friedelane has been researched along with Breast-Neoplasms* in 2 studies
1 review(s) available for friedelane and Breast-Neoplasms
| Article | Year |
|---|---|
Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer.
Breast cancer remains a major cause of death in the United States as well as the rest of the world. In view of the limited treatment options for patients with advanced breast cancer, preventive and novel therapeutic approaches play an important role in combating this disease. The plant-derived triterpenoids, commonly used for medicinal purposes in many Asian countries, posses various pharmacological properties. A large number of triterpenoids are known to exhibit cytotoxicity against a variety of tumor cells as well as anticancer efficacy in preclinical animal models. Numerous triterpenoids have been synthesized by structural modification of natural compounds. Some of these analogs are considered to be the most potent antiinflammatory and anticarcinogenic triterpenoids known. This review examines the potential role of natural triterpenoids and their derivatives in the chemoprevention and treatment of mammary tumors. Both in vitro and in vivo effects of these agents and related molecular mechanisms are presented. Potential challenges and future directions involved in the advancement of these promising compounds in the prevention and therapy of human breast cancer are also identified. Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemoprevention; Glycosides; Humans; Mice; Oleanolic Acid; Triterpenes; Ursolic Acid | 2011 |
1 other study(ies) available for friedelane and Breast-Neoplasms
| Article | Year |
|---|---|
Synthetic secofriedelane and friedelane derivatives as inhibitors of human lymphocyte proliferation and growth of human cancer cell lines in vitro.
Controlled silylation of friedelin (1) from cork smoker wash solids, a byproduct generated during processing of corkboard by steam baking, gave 3-trimethylsiloxyfriedel-2-ene (3) in high yields. Oxidation of 3 with OsO(4)/NMMO produced 2alpha-hydroxyfriedelan-3-one (cerin) (5), from which the new 2,3-secofriedelan-2-al-3-oic acid (6) was obtained quantitatively by periodic acid oxidation. Oxidation of 3 with DDQ afforded friedel-1-en-3-one (8). Reductive ozonolysis of 3 gave 2alpha,3beta-dihydroxyfriedelane, pachysandiol A (7). Compound 6 proved to be a potent inhibitor of human lymphocyte proliferation (IC(50) = 10.7 microM) and of the growth of a human cancer cell line (GI(50) = 5.4-17.2 microM). (13)C NMR data for compounds (3, 4, 5, 6a,7, and 8) are described for the first time. Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Chromatography, Thin Layer; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Kidney Neoplasms; Lung Neoplasms; Lymphocytes; Magnetic Resonance Spectroscopy; Melanoma; Molecular Structure; Oxidation-Reduction; Portugal; Quercus; Structure-Activity Relationship; Triterpenes; Tumor Cells, Cultured | 2001 |